SCHEMBL6800253

SCHEMBL6800253

COc1cccc(-n2c(=O)n(O)c(=O)c3cc(F)c(N4CCC(N)C4)cc32)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 1/20 0.43
PIM1 P11309 1/20 0.43
GSK3A P49840 1/20 0.43
GSK3B P49841 1/20 0.43
IRAK1 P51617 1/20 0.43
RPS6KA3 P51812 1/20 0.43
DYRK1A Q13627 1/20 0.43
PIM3 Q86V86 1/20 0.43
CSNK1G3 Q9Y6M4 1/20 0.43
TOP1 P11387 3/20 0.41
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
HTR7 P34969 2/20 0.36
NTRK1 P04629 2/20 0.36
MAP4K1 Q92918 2/20 0.36
FLT3 P36888 1/20 0.36
PRKAA1 Q13131 1/20 0.36
DPP4 P27487 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7014885 0.99 PRKD3 (0.42) PRKD3PIM1GSK3AGSK3BIRAK1
SCHEMBL6798617 0.91 PRKD3 (0.44) PRKD3PIM1GSK3AGSK3BIRAK1
Hydrochloric Acid SCHEMBL7007125 0.90 PRKD3 (0.43) PRKD3PIM1GSK3AGSK3BIRAK1
SCHEMBL6806917 0.89 PRKD3 (0.43) PRKD3PIM1GSK3AGSK3BIRAK1
SCHEMBL6806693 0.86 BRPF1 (0.43) HTR7MAPTMIFGAA
SCHEMBL6798420 0.84 HTR7 (0.44) HTR7MEN1KMT2AMAPTMIF
SCHEMBL6797144 0.84 PRKD3 (0.45) PRKD3PIM1GSK3AGSK3BIRAK1
Hydrochloric Acid SCHEMBL7006179 0.83 PRKD3 (0.44) PRKD3PIM1GSK3AGSK3BIRAK1
SCHEMBL6806741 0.83 PIM1 (0.43) PRKD3PIM1GSK3AGSK3BIRAK1
SCHEMBL6801118 0.82 MTNR1A (0.45) PIM1PIM3MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP claimed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US claimed
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A PRKD3 1822/4885PIM1 2808/4885GSK3A 1952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.